US Biosimilars Market: AmerisourceBergen Q&A
Q&A With Sean McGowan, Senior Director Of Biosimilars
Executive Summary
Incentives for uptake, physician education, legal barriers and patient services are among the issues covered in a wide-ranging question-and-answer session conducted with Sean McGowan, senior director of biosimilars at AmerisourceBergen.
You may also be interested in...
Pressure Mounts For German Tender Reforms
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
Teva Leapfrogs Mylan And Sandoz On Linaclotide
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Patent Settlements May Break EU Law
Patent-litigation settlements reached almost 20 years ago in the UK over GSK’s Seroxat paroxetine antidepressant may contravene EU competition law, an advocate general has advised the CJEU.